PharmaTalkRadio
PharmaTalkRadio is an internet radio podcast platform organized by the Conference Forum, providing free access to industry professionals, patient advocates, and students in medicine development. It features interviews with industry insiders discussing the latest strategies, business models, and innovations in clinical research, including clinical trials, patient-centricity, drug delivery, immuno-oncology, digital technologies, and leadership topics. The podcast also covers content from Conference Forum events.
Episodes
What to Expect at Partnerships with Sites 2026
Unlocking Unstructured Data with AI for Optimized Protocol Development
In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help sponsors avoid protocol amendments and delays. More specifically, Mike discusses: How Advarra is leveraging past IRB data sources to identify common causes of site burden, study delays and amendments Wha
Bridging Access Gaps: Sponsor-Led Enablement of Research-Naïve Sites to Expand Patient Reach
Tapping into research-naïve sites offers a strategic opportunity to expand patient access. That’s exactly what Endo did when faced with challenges activating sites for their orthopedic study. This case study shares how Endo enabled a new site through hands-on mentorship, infrastructure support, and trust-building— resulting in sustainable partnerships and broader patient reach.How naïve sites can
Building Trust-Driven Partnerships: AstraZeneca’s Concierge Approach to Accelerating Site Activation and Enrollment
AstraZeneca’s US Site Engagement Leads will share how they are reimagining sponsor-site relationships through a trust-first, high-engagement operating model that emphasizes flexibility, responsiveness, and co-creation. This session will showcase how their embedded approach to collaboration has enabled faster site activation, stronger recruitment performance, and improved data delivery—backed by re
Eli Lilly on Site Enablement: Co-Designing Solutions with Sites
A case study highlighting how Eli Lilly partnered with clinical sites to co-design practical, site-centric solutions that enhanced trial execution and operational efficiency.Fireside Guest: Shafaat Ali Khan Clinical Research Lead (CRL) Director – Investigator Engagement, Eli Lilly & CoModerator: Jyoti Angal, PhD Director, Clinical Research, Avera McKennan Hospital & University Health Cente
What a Strategic Partnership Looks Like in Practice: Inside the Takeda–Basil Collaboration That Delivered Tenfold Enrollment
This case study highlights how Basil Clinical Research and Takeda’s first-time partnership became the top global recruiter, exceeding enrollment goals by tenfold through proactive assessments, early collaboration, and inclusive design. Learn how Takeda’s shift from transactional to strategic, long-term partnerships made this success possible.Identifying and partnering with highpotential sitesIncor
Using Digital Technologies to Enhance Patient Experience and Better Manage Supply Chain
In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address: Integrating connectivity into drug delivery devices as a way to improve patient engagement and adherenceHow pharma can use drug delivery device data with predictive analytics to forecast demand and optimize productionEnabling patient-centric desig
Ensuring Sustainability Throughout Drug and Device Development
In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address how the biopharma and drug delivery industries actively move to embed sustainability into core principles, products and processes. Specifically:How pharma and suppliers can improve sustainabilityCreating designs with lower carbon footprints relativ
Utilizing AI to Facilitate Combination Product Development
In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives discuss specific examples of AI/ML usage by pharma companies through the combination product development process from iteration to commercialization as well as a discussion on how this field will evolve in the coming years.To learn more about the PODD Conference, please visit PODDC
Achieving Effective Manufacturing Scaleup for Clinical and Commercial Success
Manufacturing scaleup is a key hurdle in enabling the efficacy of new device technologies. Often this requires a mix of internal and external manufacturing and implementing a commercial control strategy across partners.In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma and CDMO executives discuss effective partnering between pharma and manufa
Advances and Opportunities in Dual Chamber Injectables
In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss progess in the development of liquid/liquid and liquid/lyo dual chamber systems. Specifically, they address: Overcoming primary container and autoinjector challenges for liquid-liquid deliveryImproving upon dual chamber reconstitution devicesFindin
How Evinova is Integrating AI into Clinical Development to Bring Big Impact to Big Pharma
About this Podcast: As pharma sponsors continually assesses how to integrate AI into their ways of working, Evinova’s Chief Technology Officer, Sean Connolly, talks about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma.Sean share his thoughts on going for low hanging fruit to encourage adoption, what he's seen in
How Bayer Reorganized Their Clinical Operations Structure for Efficiency and Cost Savings
About this podcast:Recorded at DPHARM 2025, Bayer's Dr Bernhard Glombitza reports on the development, implementation and early impact of their clinical operations reorgnization. He describes how shifting from a traditional hierarchical model to a network of highly empowered teams reduced management layers, broadening the scope of work and changed cross-country operations monitoring. Dr Glombitza d
How Amicus Embedded Patient Advocacy into its Corporate DNA
About this podcast:In this keynote from Patients as Partners in Clinical Research 2025, Amicus Therapeutics' Chief Patient Advocate, Jayne Gershkowitz, shares how their organization established and embedded patient advocacy into their core structure for lasting impact.More specifically, Ms Gershkowitz focuses on:Defining role standards and recruiting the right talent Co-creatin research with patie
Designing Clinical Trials Balancing Simplicity with Complexity
When designing clinical trials, CMOs aim to answer meaningful questions for a plethora of stakeholders. Inherently, this results in study protocols with more measures, biomarkers and data collection that both provides a platform for strategic decision-making but also impacts patient burden, operational foot-print, timelines and cost. In this panel discussion from the 2025 Chief Medical Officer Sum
Platform Approaches to Streamline Combination Product Development
Investing in developing a durable platform and strategy early leads to fewer delays throughout development. Locking requirements in early and educating teams to approach combination product development holistically lowers the time to development dramatically. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery expe
What is the State of Clinical Trial Patient Matching Right Now?
About this podcast:Recorded at the 2025 DPHARM conference, this state of the union panel convenes site, technology and pharma to discuss: Different models and the pros and cons of the deployment modelsWhat makes a great patient matching solutionPredicting what the future growth of this segment looks likeThe role of AI in this space
Balancing Innovation and Practicality in Immuno-Oncology Dose Selection
About this podcast: Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines
Leveraging Local HCPs to Decentralize Clinical Research in North Carolina
About this podcast: Recorded at the 2025 CRAACO meeting, UNC Lineberger’s Comprehensive Cancer Center shares an initiative to allow local HCPs to still provide clinical care to patients but decentralized research elements to the university system, following the FDA’s change in guidance on Form FDA 1572, which stopped requiring local healthcare professionals (HCPs) involved in DCTs to be listed if
Using Patient Engagement and Digital Innovation to Elevate Patient Insights and Outcomes
About this podcast:This podcast, recorded at the 2025 Patients as Partners Europe meeting, addresses how Novo Nordisk is consolidating patient insights to ensure greater knowledge-sharing, data integrity and traceability, addressing the unmet needs of patients, aligning product outcomes with patient expectations, and more. For more information, go to theconferenceforum.org.
What to Expect at the 2026 Patients as Partners in Clinical Research Conference
In this podcast, Kate Woda, Conference Director of the Patients as Partners in Clinical Research conference discusses what attendees can expect at the 13th annual event, including key topic areas, session highlights, presenting companies and more. For more information about the upcoming event, full agenda and speakers, visit patientsaspartnersconference.com.
The Role of the CMO in BD and M&A Partnering with Pharma
In this podcast, featuring a panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs with recent M&A and partnership experience share those experiences as well as how CMOs of other small to midsize emerging biotech companies can support the conversations and operations that take place throughout the process of business development. Specifically:Different kinds of BD deals to be
Advances in Payload Delivery and Drug Conjugation
In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss conjugation and bioconjugation approaches to make ASOs and small molecules more tolerable while improving targeting. Technologies discussed include ADCs, PDCs, SMDCs, VDCs, RDCs and AOCs. Specifically they address:Biological and chemical challenges
Building Up a CMO Team as Your Company Evolves
This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° about how to strategically approach hiring FTEs, insourcing, outsourcing and contracting to be appropriately prepared for the different stages of a biotech companies development from preclinical to early stage to late stage trials to commercialization. Specifically:Balancing the mix of hires and outsourcingHir
Beyond LNPs: Delivering Genetic Medicines with Novel Vehicles
While lipid nanoparticles are the most clinically advanced drug delivery system for nucleic acid therapeutics, they are only one tool in a toolbox of potential delivery vehicles.In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss additional tools, including polymeric nanoparticles, protein-based nan
Pfizer on Advancing Data Analysis Capabilities through A New EDC/CDMS Platform
About this podcast: This podcast comes from the DPHARM 2025 meeting. Pfizer details how they jointly co-designed and implemented an EDC/CDMS platform that’s fit for purpose, and analysis data set. This session focuses on:Engaging all stakeholders in designing the platformThe evolution of the platform focus: the transition from the majority of data coming from EDC to 3/4 of the data from third part
Insights from Tufts CSDD into Evolving Trial Partnerships Models
About this podcast: Preliminary survey results conducted by the Tufts CSDD focus on the strategic and structural growth of new trial sites and partnerships in bringing trials directly to the local communities. The preliminary survey findings also shed light on the strategic and structural growth of these new trial sites and partnerships, offering valuable insights into the evolving global clinical
ADCs, Chemotherapy, and Checkpoint Blockade in Urothelial Carcinoma
About this podcast:This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center. Dr Rosenberg focuses on: The background and previous data of immune checkpoint blockade as monotherapy and in combination with chemotherapy, in urothelial cancerThe potential role
Understanding the Immunological Effects of Radiopharmaceuticals
About this podcast:This presentation from the 2025 IO360º Summit focuses on the immunological effects of radiopharmaceuticals, presented by Chaitanya Divgi, Sr Strategic Expert, Therapeutic Innovation, at Novartis. Specifically, this podcast dives deeper into: An introduction to radioligand therapyA focus on PSMA-targeted radionuclide therapyPrelimary work on the relationship between systemic radi
How J&J Is Integrating Patient Centricity Across the Enterprise
About this episode:In this podcast, Dr Penny Heaton, Global Head of the Johnson and Johnson Office of the Chief Medical Officer, discusses: J&J’s approach to patient centricity across the enterpriseHer thoughts on balancing balancing safety and risk/benefit ratios with more engaged patients and more complex scienceMoving risk benefit assessments earlier into clinical development and the necess
Biogen's Nicole Murphy on Drug Delivery Innovation and the Acquisition of Alcyone Therapeutics
In this podcast, Nicole Murphy, EVP and Head of Pharmaceutical Operations & Technology at Biogen, discusses:Cross-functional collaboration to deliver valueHow Biogen is using AI to enhance innovationSupply chain simplificationBiogen's partnership philosophy as it relates to drug deliveryTheir recent $2 billion manufacturing investment in the Research Triangle ParkAnd Biogen's acquisition of Al
What to Expect at the 2026 IO360° Summit
In this podcast, Kate Woda, Conference Director of the Immuno-Oncology 360° Summit, discusses what attendees can expect at the 12th annual event, including key topic areas, session highlights, presenting companies and more.For more information about the upcoming event, full agenda and speakers, visit IO360Summit.com.
CMOs Working Flexibly with Consultants and Fractional Expertise
This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with CMOs and advisory solutions firms about how CMOs can work with consultants and fractional talent to stay on budget while getting the expertise needed. Specifically:Different profiles of fractional consultantsWhat to look for in a consultant and how to ensure alignment with the teamScoping the role of frac
Principles and Strategies for Designing Best-in-Class Immuno-Oncology ADCs
About this podcast:This podcast dives deep into the fundamentals of antibody-drug conjugate design, specifically focusing on the selection of targeting antibodies, cytotoxic drugs, and linkers. Presenter Dr Deepa Pakianathan highlights key strategies for constructing ADCs and the critical differentiating features that enhance therapeutic efficacy and safety. For more information, go to IO360summit
How Patient Organizations are Bridging Patient Inclusivity Gaps at the Site-Level
About this podcast:This podcast comes from the 2025 Patients as Partners in Clinical Research conference. This panel discussion demonstrates how patient advocates are bridging the divide at the site level to improve patient representation in clinical trials. More specifically, this podcast focuses on: Strategies for overcoming limited resources and lack of infrastructure, which can hinder inclusiv
How Roche Reduced Unnecessary Protocol Amendments to Impact Timeline and Cost
About this podcast: Liz Thompson, Global Development Leader, Senior Clinical Development Scientist at Roche, presented how the organization had delivered a single, cohesive protocol amendment categorization process to reduce the number of amendments and create a continuous improvement strategy, all to speed up timelines and reduce costs. This presentation comes from the September 2025 DPHARM: Disr
How to Embed Clinical Research in Rural and Frontier Health Systems
About this podcast:This session was recorded at the September 2025 CRAACO: Clinical Research as a Care Option conference.Rural sites represent untapped potential for reaching a broader array of patients and providing them access to life-changing clinical trials, but existing clinical trial infrastructure does not set rural sites up for success. Funded through the Genentech Innovation Fund, Montana
Optimizing the Value Proposition in Small Companies with Limited Budgets
This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs about how CMOs can support value creation in biotechs and how that is influenced buy the current biotech financial climate. Specifically:The importance of storytelling and leading thoughtfullyEffective prioritization and execution towards the company narrativeBalancing the team to be lean whi
From the DPHARM 2024 Archives: Biogen Pilot on Using Vocal Biomarkers to Identify Potential Participants for Clinical Trials
In this podcast from the DPHARM 2024 archives, Biogen discussed how they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to provide access to patients with a clinically validated cognitive assessment who might not otherwise have the foundation to start a conversation with their physician about their cognition. For more information
Merck on Enhancing Trial Participation, Relevance, and Impact through Patient and Community Engagement
At the March 2025 Patients as Partners conference, Merck presents how they advancing patient and community engagement through targeted initiatives designed to improve trial participation, relevance, and long-term impact. Key topics include:Identifying and addressing patient and community needsStrategies for earning trust and fostering sustained engagementKey collaborations and partnerships driving
Ensuring Continuity in Patient Insights to Strengthen Medicine Development
Summary: This session was recorded at the March 2025 Patients as Partners conference. In this session, Pfizer addressed how they were working to ensure continuity in the patient insights they were collecting, throughout the product life cycle. This included: Approaches for aligning internal processes to facilitate the seamless flow of patient insights from early-phase to late-phase teamsSuggested
Accelerating Patient Enrollment in Clinical Trials by Deploying a Product Model Approach
Summary: From the DPHARM Archives, this podcast was recorded at the September 2024 DPHARM conference. In this podcast, BMS present how they specifically targeted the challenge of recruiting patients for clinical trials, aiming to make the process faster and easier. By bringing trials directly to patients, their ultimate objective was to significantly expedite patient enrollment. In this case examp
Stanford's Dr Crystal Mackall on the Evolution of and Future Directions in Cell Therapy
About this podcast:Recorded at the 2025 Immuno-Oncology 360º Summit, Stanford University's Dr Crystal Mackall shares work from her lab developing GD2-targeting CAR T cell therapy for the treatment of deadly pediatric brain tumor, as well as broader lessons on the evolution of cell therapy, and her forward-looking perspective on shaping the next generation of cancer treatments.For more information,
De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing
Summary:Rescuing a clinical trial and choosing to switch vendor's mid-trial are some of the most expensive decisions biotech CMOs can make. These rescues require a significant amount of time, money and energy and may not even address the root issue behind a trial's poor performance. In this podcast, Raul Lima, SVP, Strategic Clinical Operations, inSeption Group, discusses a scaffolding approach th
Balancing Between Concentration and Volume when Developing Patient-Centric Biologics
Summary:When developing patient-centric products for biologics, different doses, expressed by different combinations of volume/concentration may require different delivery devices. As a result, it takes a great deal of time and effort in planning and coordinating the formulation and device activities. In this podcast, Pharma and Drug Delivery executives from Nanoform, Pfizer, GSK, Takeda and Kyman
Directors' Talk DPHARM 2025 - AI Sessions; Part III
In this podcast series, DPHARM Director Tracey Kimball with Valerie Bowling, Executive Director of the Conference Forum, break down what to expect at DPHARM 2025. Part III of this podcast series covers sessions addressing AI in Clinical Trials.
Innovations in Manufacturing to Make CAR-T More Accessible and Affordable
Summary:Accessibility to CAR-T is limited by traditional manufacturing, with its associated challenges and high cost. Moffitt Cancer Center's Chief BioEngineering Officer, Dr Greg Sawyer, highlights Moffitt's significant progress in enhancing T cell potency and boosting efficacy through engineering strategies. Dr Sawyer discusses assays enabling precise asessment of T cell potency, developments in
Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches
Summary:In this podcast, Pharma and Drug Delivery executives from Novartis, AstraZeneca, Merck and Quotient Sciences discuss traditional and novel approaches to improve the oral delivery of peptides including:The biopharmaceutics of oral peptide and the use of permeation enhancersAlternate sites for the delivery of oral peptides throughout the GI tractImproving oral exposure through ingestible dev
Catalyzing Change: The Business Imperative of Patient-Centric Drug Development
Summary: In this podcast, Dr Anthony Yanni, SVP, Head of Patient Centricity at Astellas, presented the business rationale for patient-centric medicine development, how it's disrupting the pharmaceutical industry and why companies have to act swiftly to remain competitive. Dr Yanni discusses how to align medicine development with healthcare delivery and the necessary cultural transformation that is
How Emerging Biopharma CMOs Can Better Partner with Patient Organizations
This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs across indications about how CMOs can better develop drugs patients want and derisk development by partnering with patient organizations. Specifically, the panelists address:Patient voice driving drug development forwardSupporting health equity and patient access after approvalBuilding genuin
Joint Site and Sponsor Perspectives on Innovative Solutions Addressing Sites Challenges
Summary:In this session, pharma sponsors and sites gather to present innovative solutions to solve site challenges in workforce and capability gaps, increasing technology burden, patient enrollment and managing clinical trial protocol complexity. They discuss efforts to address those challenges, early impacts and outcomes. In this panel: Dennis Salotti, MS, MBA, Executive Director & Head of Cl
What to Expect at the CRAACO: Clinical Research as a Care Option 2025 Event
Conference Forum Director Valerie Bowling and CRAACO Producer Danny McCarthy break down what to expect at the 2025 CRAACO program. This podcast covers the keynotes, panels and key themes for this year's event, including: How to develop a clinical research program within a community cancer center, with Dr Brian Slomovitz, Mount Sinai Medical Center Miami BeachTurning clinical environments into lear
Directors' Talk PODD 2025 - Keynotes & Key Themes
PODD: Partnership Opportunities in Drug Delivery Directors Valerie Bowling and Andrew Goldstein break down what to expect at PODD 2025. This podcast covers keynotes and key themes for this year's event, including:Regeneron Co-Founder and CSO, Dr George YancopoulosNovo Nordisk Chief Scientific Advisor, Dr Lotte Bjerre KnudsenMIT's Robert LangerPatient Keynote, Jimi OlaghereNortheastern University's
Enhanced Strategic FDA Collaboration: Working with CDER and CBER
This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs across indications about how CMOs can best support their regulatory teams and engage with the FDA and other regulators. Specifically, the panelists address:Engaging with the FDA on a peer-to-peer levelEffectively negotiating about innovative approaches that may be outside of guidelinesHow to
Biomaterial Implants to Reduce Patient Burden and Improve Adherence
This podcast features a panel discussion from the 2024 PODD Conference with biopharma leaders about biomaterial approaches to develop implants that can deliver molecules and optimize for dose frequency. Specifically:Defining biocompatible materials and biomaterialsDifferences between small and larger moleculesBenefits and challenges of implantsTo learn more about the PODD conference, please visit
Are Site Networks the Solution to the Industry Productivity and Recruitment Challenge?
Summary:The consolidation of independent clinical trial sites into larger, integrated networks represents a strategic evolution in clinical research. This panel from the 2024 DPHARM conference discusses whether or not this level of consolidation can bring new researchers and new sites into clinical research, and lead to reduced risk to sponsors, increased predictability, streamlined site operation
2025 Biotech Markets & Immuno-Oncology Outlook
Summary:Mizuho Securities Analyst, Dr Graig Suvannavejh, joined the 2025 Immuno-Oncology 360º Summit to share an outlook on the IO biotech market, high-level thoughts on the IO space, and public IO company case studies to illustrate the market's perception of what's happening in IO. More specifically:The current tailwinds working for and headwinds working against investment in biotechThe increasin
Directors' Talk DPHARM 2025 - Pharma from the Trenches; Part II
In this podcast series, DPHARM Director Tracey Kimball with Valerie Bowling, Executive Director of the Conference Forum, break down what to expect at DPHARM 2025. Part II of this podcast series covers the 16 Pharma from the Trenches track case studies.
Directors' Talk DPHARM 2025 - Keynotes & Key Topics; Part I
In this podcast series, DPHARM Directors Tracey Kimball and Valerie Bowling break down what to expect at DPHARM 2025. Part I of this podcast series covers keynotes and key topics for this year's event, including:Former Merck CEO, Ken FrazierFormer Head of FDA, Scott GottliebCRISPR Gene Therapy Patient Keynote, Victoria GrayTuft's Ken GetzHow DPHARM is tackling AIWhat to do about Protocol Complexit
Streamlining Effective Patient Engagement through Pharma-Patient Advocacy Collaboration
About this podcast: Partnerships between industry and patient advocacy groups supply medicine development with critical patient expertise, insights and experience on the journey towards greater patient centricity. This podcast focuses specifically on the role of patient advocacy groups in medicine development in providing a direct, and often untapped, resource for patient insights, community conn
Lessons Learned in the Development and Introduction of Closed Loop Systems
This podcast features a panel discussion from the 2024 PODD Conference with pharma, medtech and academic leaders about technological development and patient and clinical adoption of closed-loop systems. Specifically:Success in diabetes and lessons for other indications like oncology and CNSNew frontiers in improving closed-loop therapiesIncreasing access across therapy areasTo learn more about the
Best Practices and Potential Pitfalls Enriching Clinical Trials with PROs
Patient-reported outcomes (PROs) are increasingly recognized by regulators, clinicians, and patients as valuable tools to collect patient-centered data. This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs about how to incorporate PROs into clinical trials in ways that improve probabilities of success while avoiding common mistakes. Specificall
Operationalizing the Patient Voice for Long-Term Protocol Planning and Execution
Summary:This podcast from the 2024 DPHARM conference showcases the value of patient engagement as a core strategic investment by focusing on the connection between patient engagement and tangible patient benefits / long-term business sustainability. The case example from Roche uses patient burden and protocol complexity in late-stage clinical development to demonstrate how this connection can be d
Navigating Data Quality and Scalability Challenges when Using Real-World Data from EHRs
Summary:In this podcast from the 2024 CRAACO: Clinical Research as a Care Option conference, Dr Meredith Zozus, UT Health San Antonio, walks through several studies illustrating differences in data quality and scalability using EHRs in the conduct of structured protoocls versus retrospective studies using EHR. The results highlight the important methods and approaches for using EHR data in clinicl
Addressing the Realities of Scaling T-Cell Therapies for Patient Access and Affordability
Summary:This podcast delves into the critical challenges of scalability in T-cell therapies (including CAR-T, TILs, and TCR-T). The panelists discuss the primary obstacles hindering the increased availability of T-cell therapies to patients, the most promising upcoming approaches to enhance access, the greatest opportunities to improve efficiencies and scalability, and the developments in the near
The Current Status of Patient Centricity in Medicine Development
Summary:This podcast focuses on the current state of patient centricity within the biopharmaceutical industry, how it's being implemented, operationalized and scaled within organizations, and showing the tangible value of engaging patients. Dr Matthew Reaney, Scientific Lead, Patient-Centered Solutions at IQVIA, speaks with Dr Anthony Yanni, SVP, Head of Patient Centricity at Astellas, to share t
Patients as Partners Caregiver Keynote - The Life-Changing Power of a Clinical Trial
Summary:In this podcast, recorded at the 2025 Patients as Partners in Clinical Research conference, patient advocate and caregiver Dr Justin Hopkin, University of Rochester, describes his family's journey before, during and after his son was diagnosed with a rare, life-threatening disease. Dr Hopkin talks about the process of getting a diagnosis, the critical role of a clinical trial for his son,
Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape
Summary:This podcast, recorded at the 2025 Immuno-Oncology 360º (IO360º) Summit, explores the clinical and market implications of emerging data on bispecific antibodies targeting PD-1 and VEGF and their potential to disrupt existing immunotherapy paradigms.More specifically: Assessing the potential of this therapeutic approach to challenge established treatments like pembrolizumab by targeting bot
Sustained Release Innovations to Reduce Patient Burden
This podcast features a panel discussion from the 2024 PODD Conference with pharma and biotech leaders about approaches and challenges in developing sustained release and long acting injectable formulations of therapeutics. Specifically:Contrasting approaches for both biologics and small moleculesNext generation technologies to provide less frequent administrationScalable and sustainable ways to p
How Pharma Is Adopting Generative AI Across Clinical Development
Summary: In this session from DPHARM 2024, pharma experts in data science, digital innovation and development discuss the prerequisites for generative artificial intelligence (GenAI) to work well in large pharma organizations, the change management required to implement GenAI adoption, use cases and lessons learned, ensuring GenAI use is fit-for-purpose, and more. For more information, go to DPHAR
Tufts Center for Study of Drug Development on Evolving Clinical Trial Partnerships
Summary: New clinical trial execution models have been introduced over the last decade, providing local communities with more direct access to clinical research through remote sites, retail pharmacies, mobile units, site staff embedded in clinical care settings, and more. In this session, recorded at the 2024 CRAACO: Clinical Research as a Care Option conference, Joan Chambers of the Tufts Center
New Approaches to Achieve Targeted Brain Delivery Without Increasing Toxicity
This podcast features a panel discussion from the 2024 PODD Conference with pharma and biotech leaders about formulation and physical approaches to achieve targeted brain delivery. The panelists discuss challenges and updates, patient acceptability and recent approvals for a variety of approaches including:Nose-to-brain deliveryIntrocerebroventricular injectionsBlood-brain-barrier disruption via e
Partnering with Patients in Clinical Development Using the Biopsychosocial Model
Summary: This podcast covers how a co-creation and collaboration was formed between Abbott, the National Blood Clot Alliance and Luminous to gather qualitative insights exploring motivations in a key patient population for participating in clinical research. The podcast additionally covers how the partnership has influenced patient engagement in a large healthcare organization, the resulting shift
Vaccine Delivery Innovations
This podcast features a panel discussion from the 2024 PODD Conference with pharma and biotech leaders about the technical innovation in the vaccine space within R&D over the past several years as well as the challenges and opportunities around the uptake and implementation of these technologies. Specifically:Barriers to implementation of technological advancementsHow the vaccine marketplace d
How PALADIN Consortium Aims to Enhance Efficient Patient Advocacy-Industry Collaborations
Summary:In this podcast, PALADIN Consortium Committee Co-Chairs, Deirdre BeVard of CSL and Dr Len Valentino of World Federation of Hemophilia USA, discuss how the pre-competitive group is creating resources aimed at enhancing and speeding up industry-patient advocacy collaborations. For more information on PharmaTalk Radio podcasts, you can go to theconferenceforum.org. For more information on pat
What CMOs Need to Know and Do When Preparing for Product Launch
CMOs play a critical role in ensuring activities prior to approval lead to a successful launch. In this podcast, originally recorded as a session at the 2024 CMO Summit 360°, panelists discuss the role of the CMO in preparing for a new product launch, including planning, timing, activities and hiring prior to PDUFA, including:The timing and strategy of building out medical affairsStrategic imperat
What to Expect at the 2025 Patients as Partners EU Conference
Valerie Bowling, Executive Director of Patients as Partners Europe conference, discusses what attendees can expect at the 9th annual conference, including key topic areas, session highlights, presenting companies and more.For more information about the upcoming event, full agenda and speakers, visit https://patientsaspartnerseu.com/
Understanding Financial Barriers to Getting More Coverage for Patients in Clinical Trials
Summary:In this podcast, recorded at the 2024 Clinical Research as a Care Option (CRAACO) event, Donna O'Brien, Manatt Health, Trevan Locke, Duke-Margolis, and Denise Snyder, Duke University School of Medicine, discuss the financial barriers to getting coverage for clinical trials, coverage by sponsors vs standard of care and new developments for the audience to be aware of. They also cover: What
How Montefiore Gets Early Stage Clinical Trials to Under-Resourced Communities
Summary:Dr David Levitz, Medical Director of the Early Phase Program at Montefiore Einstein Cancer Center, talks about how the center has been able to offer its community access to early stage clinical research. Dr Levitz brings the audience through the necessary infrastructure, dedicated team, interdepartmental collaboration, higher-up support, recruitment and partnership strategies required to m
Investment Trends in Immuno-Oncology
Summary:In this podcast, recorded at the February 2024 IO360º summit, biopharma, finance and investment experts discuss the fundability features of IO biotechs, and the current pharma needs that will drive potential partnerships or M&A. Moderater:Axel Hoos, MD, PhD, Former CEO, Scorpion TherapeuticsPanelists: Irina Margine, PhD, Principal, Biotech Private Equity, Wellington ManagementKhalil Ba
Recommended
Doctor Zhivago Slow Read
The Swerve Podcast: Obscure Topics | Conspiracy Theories
The Young and Called Podcast .
Conspiracy Files with Paige Carter
World News Tonight with David Muir
Bad Friends
Iran War Daily
MosaLingua Language Lab
Grind Hard Mix Show
The Articulate SpecialOne
Difference Makers
The Loop
